AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)

AngioDynamics shares are finally showing signs of positive momentum. Click for this ANGO stock update and see if it is the ...

AngioDynamics anticipates $336M-$341M FY 2027 net sales while targeting $13M-$16M adjusted EBITDA

Q4 FY 2026. Management view "We capped off a year of consistent execution across the business with a strong fourth quarter. Full-year ...
TCTMD

TCT 518: Debulking of Right Atrial Mass Via Mechanical Thrombectomy With Angiovac in a Patient With Metastatic Pancreatic Cancer

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Nasdaq

AngioDynamics Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...
Medscape

Angiovac System Removes Large High-Risk Clots in Vasculature

November 29, 2011 (New York, New York) — The Angiovac endovascular clot removal system (Vortex Inc.) appears to be safe and effective for the treatment of massive pulmonary emboli and removal of large ...